The Readout Loud: Recent Episodes

STAT

Podcast by STAT

Josh Schimmer and Eric Schmidt, two longtime analysts teaming up at Cantor Fitzgerald, join us for a back-to-school conversation as biotech enters the busy back third of 2023. We also discuss the latest news in the life sciences, including some scientific evolution at Biogen, new leadership at Illumina, and the future of CRISPR medicine.

We discuss how Vivek Ramaswamy, fresh off his headline-grabbing debut at the first Republican presidential debate, went from a drug industry entrepreneur to a GOP rising star — and how his former biotech colleagues are reacting to it. We also explain the latest news in the life sciences, including a curious data leak and the family business of a famed biotech inventor.

Our colleague Jason Mast joins us to explain how the approval of a landmark gene therapy for Duchenne muscular dystrophy set in motion a frantic race to get children treated before their 6th birthdays. Then, HSBC Managing Director Jonathan Norris calls in to discuss why so many biotech startups are facing financial bridges to nowhere.

In the wake of a massively important clinical trial of Novo Nordisk’s obesity drug Wegovy, our colleague Elaine Chen joins us to explain what we know and don’t know about data that could change the practice of medicine. Then, Mizuho Securities biotech strategist Jared Holz calls in to discuss whether explosive popularity of obesity treatments could help create the first trillion-dollar drug company.

First, we discuss how some recent layoffs and a reverse merger mean for biotech in 2023. We’ll also discuss the latest news in the life sciences, including a dramatic saga in ocular medicine, the volatile business of Covid-19, and some major milestones in gene therapy.

First, we discuss why Wall Street was less than convinced by Biogen's attempt to assuage concerns about its credibility. Then we explain an insider trading scandal that bridges biotech and elite-level soccer, the latest concerns over Wegovy, and the rest of the week's news in the life sciences. We also break some bittersweet news, with the help of some headline names from around biotech.

Neil Kumar, CEO of BridgeBio, joins us to talk about how his small company came to develop what could be a big drug — and why classical Greek literature remains relevant. We also discuss the latest news in the life sciences, including the abrupt resignation of the celebrity scientist who led Stanford University and the implications of tornado damage at a Pfizer plant.

Our colleague Megan Molteni joins us to explain the evolving science suggesting products like Wegovy are less weight loss drugs than treatments for human desire. We also explain why this summer is shaping up to be a pivotal moment for the treatment of Alzheimer’s and discuss our befuddlement with the latest social media platform.

Our colleague Elaine Chen joins us to explain how the era of Wegovy could be short-lived in light of powerful new weight-loss medicines from Eli Lilly. Then, John Jacobs, the new CEO of Novavax, stops by to explain his plan to right the ship at a company that has struggled to make the most of its potent Covid-19 vaccine.

Our colleague Bob Herman joins us to explain his year-long investigation into some brazen conflicts of interest in the world of prescription drug pricing. Then, STAT's Helen Branswell calls in to walk us through a news-packed week for vaccines, including weighty decisions for Covid-19 and RSV.

Our colleague Allison DeAngelis joins us to share her reporting on how the handsomely funded Laronde Therapeutics, billed as “Moderna 2.0,” ran into behind-the-scenes problems with its scientific data. We also discuss how Biogen's boardroom scandal has roiled a company that was supposed to be entering a new era.

STAT Washington correspondent Rachel Cohrs joins us to explain Merck's lawsuit against the federal government and why the company believes drug pricing negotiation is “tantamount to extortion." We also discuss the health effects of Canadian wildfires, the highlights of the year’s biggest cancer research conference, and what could be a watershed moment in the treatment of Alzheimer’s.

Our colleague Lizzy Lawrence joins us to explain the shocking story of a medical device company that sold fake implants and the warped system that made the scam lucrative. We’ll also preview the year’s biggest cancer research meeting and discuss a surprising twist with novel weight loss medicines.

As hospitals and health care companies are racing to implement large language models like ChatGPT into their businesses, STAT reporter Casey Ross joins us to explain what experts want the world to know before embracing generative AI. We also discuss the latest twist for Sarepta Therapeutics and the quest to develop more potent weight loss medicines.

Jared Holz, biotech strategist at Mizuho Securities, joins us to explain why federal regulators are suing to block Amgen's $28 billion merger with Horizon Therapeutics and what it means for the drug industry. We also discuss the latest on Sarepta Therapeutics and its gene therapy for Duchenne muscular dystrophy, a turnaround story in the making at the Belgian drug maker Galapagos, and the effort to secure approval for a maternal RSV vaccine.

We discuss a Senate hearing that put major pharma CEOs in the same room with the middlemen they love to blame for rising drug prices, with mixed results. We also explain what is a massive week for Sarepta Therapeutics, the FDA, and the future of gene therapies for rare diseases, plus the latest news in the life sciences.

Eli Lilly’s investigational medicine for Alzheimer’s met its goals in an all-important clinical trial, and we explain the results, their implications, and the backstory of what could be a blockbuster drug. We also discuss the latest news in the life sciences, including a busy week of earnings, a long-awaited FDA approval, and the highlights from STAT’s Breakthrough Summit in San Francisco.

Andrew Joseph, STAT's Europe correspondent, joins us to explain the EU's sweeping proposal to overhaul how new drugs are regulated on the continent — and why the pharmaceutical industry is fighting it. We also discuss the latest news in the life sciences, including Lilly's surging business, a pair of new drug approvals, and a novel idea in Alzheimer's disease.

Our colleague Helen Branswell joins us to explain the latest news on Covid-19 boosters and the implications of a Marburg outbreak in Equatorial Guinea. Then we dive into the long history of a gene therapy from Sarepta Therapeutics, a polarizing medicine that promises to change the lives of patients with Duchenne muscular dystrophy. We also break down the rest of the week’s biggest news in biopharma, including some billion-dollar deals and the retirement of perhaps the most storied executive in the business.

Jeremy Levin, CEO of Ovid Therapeutics, joins us to discuss a judge’s decision to overturn the FDA approval of an abortion pill and why he believes it’s the biggest threat to the biopharma industry in 50 years. We also cover the biggest news in the week of biopharma, including an update from Moderna, dispatches from a trip to FDA headquarters, and who Sen. Bernie Sanders has in his sights next.

Our colleague Matthew Herper joins us for a deep dive into Illumina, explaining how the biggest company in genome sequencing lost the faith of shareholders and painted itself into a corner. We’ll also discuss the latest news in the life sciences, including a look at what’s ahead in biotech for the second quarter of the year, and why Johnson & Johnson investors are happy the company is proposing to part with $9 billion.

We explain how biotech is affected by a bizarre situation involving smuggled monkeys, international intrigue, and a criminal investigation. We also discuss what leads to generic drug shortages, whether every major pharmaceutical firm needs a weight-loss drug, and what it means when drug company cancels a conference appearance.

We discuss the theatrical merits and actual implications of Moderna CEO Stéphane Bancel's appearance before a committee led by Sen. Bernie Sanders. We also talk about the latest news in the life sciences, including Regeneron Pharmaceuticals' latest data for its powerhouse drug Dupixent, an about-face for Sarepta Therapeutics, and how the FDA appears to view biomarkers in neurological diseases.

STAT reporter Bob Herman joins us to explain how treatment algorithms powered by artificial intelligence are being used more frequently by Medicare Advantage plans to deny claims, even when continued treatment is medically justified. We’ll also discuss the latest news in the life sciences, including the continued fallout of the run on Silicon Valley Bank, the return of Carl Icahn, and a long-awaited pharmaceutical megadeal.

FDA Commissioner Robert Califf joins to discuss his first year on the job, the future of drug approvals, and how Duke basketball will do without Coach K. Then STAT’s Elaine Chen explains how powerful new weight loss medicines are reshaping medicine, the drug industry, and the society at large. We also discuss the latest news in the life sciences, including the results of a new Alzheimer's disease study and a potential breakthrough in cardiovascular medicine.

Our colleague Allison DeAngelis joins us to explain how the latest CRISPR breakthrough is shaping up to be a free-for-all among a multitude of companies and labs, including some of the biggest names in biotech. We also discuss the latest news in the life sciences, including Eli Lilly slashing the cost of insulin, succession at the FDA, and how pandemic boom times have turned to bust.

STAT’s Ed Silverman joins us to explain how an escalating fight between Vertex Pharmaceuticals and insurance companies has left patients and families caught in the middle. We also discuss the latest news in the life sciences, including the demise of a one-time unicorn, Moderna’s difficult second act, and an official biotech presidential run.

Vas Narasimhan, CEO of Novartis and the new chairman of PhRMA, joins us to discuss the industry’s struggles in Washington and whether the deflated biotech sector is still overvalued. We also dive into the latest news in the life sciences, including Moderna's promise of no-cost Covid-19 vaccines and biotech entrepreneur Vivek Ramaswamy's potential run for president.

Helen Branswell, STAT’s senior writer covering infectious disease, joins us to explain the sudden resurgence of a bird flu virus called H5N1 and why experts are watching the situation closely.

STAT Washington correspondent Rachel Cohrs joins us to explain the looming end of Covid-19's status as a federal emergency and what that does and doesn't mean for public health. We also dig into the most interesting stories from a busy week of pharmaceutical earnings and discuss a legal setback for Johnson & Johnson.

George Scangos, the CEO of Vir Biotechnology, joins us to discuss his retirement and offer some perspective and lessons from a remarkable, 40-year career in biotech. We also chat about the latest news in the life sciences, including an FDA advisory meeting debating the necessity for annual Covid vaccinations, and a surprising, but perhaps not, rejection of Eli Lilly’s Alzheimer’s disease treatment.

Journalist Nathan Vardi joins us to talk about his new book delving into the race to develop the lifesaving cancer drug now called Imbruvica, involving a Scientologist CEO and secretive investor seeking redemption after the worst trade of his life. We also discuss the latest news in the life sciences, including new vaccines for a vexing infection and the future of mRNA.

With the 2023 J.P. Morgan Healthcare Conference drawing to a close, we look back on the biggest news of the meeting, what it means for the year in biotech ahead, and whether the industry's biggest annual gathering might finally have outgrown its host city.

First, we delve into a sweeping congressional investigation into the FDA's approval of the last treatment for Alzheimer's disease and what it means for the next one. We also preview the upcoming J.P. Morgan Healthcare Conference and the biggest biotech events of 2023.

We look back on the biggest biotech stories of 2022 and how, despite some meaningful advances in Alzheimer's disease and gene therapy, the industry seems stuck in a sentiment rut. We also discuss the latest news in the life sciences, including a pair of indicted CEOs and the debate over how much an oft-debated new medicine should cost.

Katie Palmer, STAT's health tech correspondent, joins us to explain how the explosive popularity of telehealth is putting sensitive patient information into the hands of Facebook, TikTok, and other big tech firms. We also discuss the latest news in the life sciences, including highlights from a big hematology conference, a disastrous biotech IPO, and the downside of being a good quote.

STAT's Elaine Chen joins us to explain how the escalating demand for a potent diabetes drug is putting patients with obesity in a difficult situation. We also discuss a curious trend in biotech investing, the future of Illumina, and another sentencing in the Theranos saga.

STAT Washington correspondent Rachel Cohrs joins us to explain how PhRMA, the all-powerful lobbying group, lost its edge in a fight over drug-pricing negotiation. Damian gives us the inside scoop on CTAD, the big Alzheimer's disease research conference, where Eisai and Biogen presented groundbreaking data on their treatment called lecanemab. We also discuss the FDA approval of a microbiome drug for the treatment of a bowel disorder and the potential for a big acquisition of Horizon Therapeutics.

How do Alzheimer’s drugs even work? Can biotech people bake? And do we even like one another? Recorded live from the 2022 STAT Summit, we discuss the failure of an Alzheimer’s disease treatment from Roche, the unexpected success of a competing one for Eisai, and some unpredictable questions from our audience.

STAT Washington correspondent Sarah Owermohle joins us to explain how this week's midterm elections will affect health and medicine, and what the politicization of the pandemic means for the future of science in the U.S. We also discuss the incoming CEOs of Biogen and Seagen, plus a pair of biotech collapses.

Our colleague Matthew Herper joins us to discuss his thoughtful, personal story on how the biotech revolution that brought us genome editing, Covid-19 vaccines, and lifesaving medicines could run aground if humanity can't get out of its own way.

Our colleague Sarah Owermohle joins us to discuss how pandemic shutdowns, Covid-19 vaccines, and the prospect of arresting Anthony Fauci have become campaign rallying cries in midterm elections. We also discuss the latest news in the life sciences, including the potential effects of federal drug-price negotiation and the virtues of befriending Pharrell Williams.

Lawyer and bioethicist Holly Fernandez Lynch joins us to explain a watershed test of the FDA's authority to revoke drug approvals. And STAT's Helen Branswell calls in to discuss the headline-grabbing research at Boston University involving a lab-developed version of the virus that causes Covid-19.

STAT Washington correspondent Rachel Cohrs joins us to explain the abrupt departure of the CEO of BIO, the lobbying group representing biotech on Capitol Hill, and its wider implications. We also discuss the latest news in the life sciences, including the future of mRNA, a promising startup closing its doors, and Biogen’s search for a new CEO.

The newest Nobel laureates got their phone calls from Stockholm this week, and STAT science writer Megan Molteni joins us to explain their prize-winning work in medicine and chemistry. We also discuss the latest news in the life sciences, including the state of biotech dealmaking and the evolution of Amylyx Pharmaceuticals.

Lecanemab, a new Alzheimer's treatment from partners Biogen and Eisai, succeeded in a pivotal clinical trial, and we explain the surprising development and its sweeping implications. Then, oncologist Mikkael Sekeres joins us to talk about his new book, which is a history of the FDA and an insider’s look at one of the agency’s most contentious drug approval hearings.

Heidi Tworek, a professor at the University of British Columbia and expert on public health communication, joins us to discuss President Biden's declaration that "the pandemic is over" and how leaders around the world are talking about Covid-19 as it enters its third year. We’ll also discuss the latest news in the life sciences, including the twilight of the SPAC boom, the coming evolution of genome editing, and the next big trial in Alzheimer’s disease.

Our colleague Katie Palmer joins us to explain a burgeoning trend in pharmaceutical advertising that has health policy experts alarmed. We also discuss the White House's investment in biotech, a bellwether IPO, and the latest twist in the Merck-Seagen saga.

Our colleague Matthew Herper joins us to discuss how Illumina, the biggest company in genomic sequencing, got into an $8 billion predicament. We also discuss a dramatic development for a new ALS treatment, the latest in cancer research, and a well-funded new player in biotech venture capital.

Our colleague Megan Molteni joins us to explain the scientific discoveries, rampant hype, and Silicon Valley billions behind the burgeoning field of longevity research. Then, we discuss the remarkable career of Stelios Papadopoulos, the venerated Godfather of biotech who faces the daunting task of saving Biogen.

Our colleague Helen Branswell joins to explain the Covid-19 booster debate, the Biden Administration’s monkeypox response, and the long career of the soon-to-step-down Anthony Fauci. We also discuss the latest news in the life sciences, including a milestone for gene therapy, the tentative return of an IPO market, and the venture capital league table.

First, STAT's Tara Bannow joins us to discuss how private equity's mounting interest in autism care has created an untenable situation for many parents in the U.S. We also explain the implications of Bluebird Bio's long-awaited FDA approval, a controversial treatment for ALS, and the ups and downs of Merck's reported interest in buying Seagen.

Are biotech's fortunes finally changing? Is Big Science impeding actual science? And what will Medicare negotiation mean for drug prices? STAT's Jason Mast joins us to discuss Jim Wilson, a pioneering scientist synonymous with the rise of gene therapy who staffers say presided over a toxic, abusive workplace. We also explain the latest news in the life sciences, including a multibillion-dollar deal, a novel approach to treating schizophrenia, and what the Senate drug pricing legislation means for the pharmaceutical industry.

Is drug pricing reform really happening this time? Are things finally turning around for biotech? And is it ever wise to tweet your food? Rachel Cohrs, STAT's Washington correspondent, joins us to explain how congressional Democrats are on the verge of a coup in drug pricing — and what could still stand in their way. We also discuss the latest news in the life sciences, including some hotly anticipated data from Alnylam Pharmaceuticals, a $4 billion buyout deal, and other surprisingly good news for biotech.

Can monkeypox be contained? Are snortable Covid-19 vaccines on the way? And when is a GIF worth $200,000? STAT's Helen Branswell joins us to explain the latest in the monkeypox outbreak and how health authorities are struggling to contain it. We also discuss the latest news in the life sciences, including some faked Alzheimer’s data, a brewing FDA controversy, and what it means when a scientific discovery gets turned into an NFT.

Does any CEO deserve $500 million a year? How did Moderna hit it big? And who wants to run Biogen? STAT's Bob Herman joins us to explain why health care CEOs get paid so much — and why company-reported numbers don't tell the full story. Wall Street Journal reporter Peter Loftus calls in to talk about his book chronicling how Moderna went from secretive startup to household name. And we discuss the latest news in the life sciences, including Amazon's latest multibillion-dollar foray into primary care and Biogen's search for a new CEO.

Can CRISPR edit out a heart attack? What happens on #GutTok? And is health care recession-proof? Sek Kathiresan, cardiologist and CEO of Verve Therapeutics, joins us to explain the company's work on preventing heart disease with genome editing. Then, STAT's Isabella Cueto joins us to discuss "Hot girls have IBS," an internet in-joke that evolved into a movement for people with chronic illness. We also break down the latest news in the life sciences, including a long-awaited victory for Novavax and ostensible good news for biotech.

Is the era of the unicorn over? What's gotten into the FDA? And will a NASH drug ever work? Our colleague Allison DeAngelis joins us to explain how the prolonged downturn for biotech stocks is stoking anxiety among venture capitalists. We also discuss an FDA plot twist for a novel ALS treatment, a second shot for a once-promising liver drug, and the latest in the Covid-19 pandemic.

How do you stop a Covid surge? Why are clinical trials so white? And what are the limits of HIPAA? Our colleague Eric Boodman joins us to discuss whether an oft-cited federal law can shield reproductive health data from state law enforcement in the wake of Roe v. Wade being overturned. Then, STAT's Angus Chen calls in to relate the story of an ambitious study and the quest to finally make clinical trials more equitable. We also explain a momentous FDA meeting and the debate over just what the Covid-19 vaccines of the future should contain.

Just how powerful is the FDA? Is Merck about to spend $40 billion? And what's a "Puff Bar"? STAT Washington correspondent Nicholas Florko joins us to discuss the FDA's decision to ban the sale of Juul Labs vaping products and a proposal to reduce the amount of nicotine in cigarettes. We’ll also explain the latest news in the life sciences, including a rumored blockbuster buyout and the next Theranos verdict.

Will biotech stocks ever recover? How well do Covid-19 vaccines work for kids? And can anything stop the amyloid hypothesis? Longtime biotech investor Les Funtleyder joins us to explain why the recent interest rate hike is bad for biotech and just what it will take for the industry to get out of its slump. Then, vaccinologist and FDA adviser Paul Offit calls in to talk about the impending authorization of Covid-19 vaccines for young children and what it means for the future of the pandemic. We also explain the latest disappointing clinical trial in Alzheimer's disease and some perplexing data on Pfizer's Covid-19 antiviral.

When is data "practice-changing"? How many Covid-19 vaccines do we need? And what does it mean when the FDA asks for more time? With the world's largest cancer conference just concluded, we explain the most important data presented at the meeting, including a blockbuster clinical trial that promises to change the treatment of advanced breast cancer. We also discuss an FDA controversy in the making, a pair of new Covid-19 vaccines, and the frustrating process of finding new treatments for depression.

Will gene therapy ever live up to expectations? Can anyone break up the genomics monopoly? And is innovation actually bad for biotech? This week, health care strategist Jared Holz of Oppenheimer joins us to discuss the weekend's big oncology conference and what it will take to change Wall Street's dire view of the drug industry. We also discuss a weighty FDA meeting on gene therapy, the potential of a $100 genome, and how the expanding monkeypox outbreak is creating challenges for public health agencies.

ovid vaccines for the youngest kids are up for review, but which jab — Moderna or Pfizer — will parents choose? What’s on tap for ASCO, the biggest cancer research conference of the year? And a biotech CEO has been arrested in an alleged murder-for-hire scheme. First, we chat about the latest news in the life sciences. Then, we’re joined by physician and parent Jeremy Faust to discuss his take on the Covid vaccine data for children under 5.

What happens when the White House runs out of Covid-19 money? Why are kids suddenly getting mysterious infections? And who's going to hire Martin Shkreli? First, STAT's Helen Branswell joins us to explain the medical mystery of hepatitis appearing worldwide in young children, plus the sudden outbreak of monkeypox. Then, STAT Washington correspondent Rachel Cohrs calls in to discuss how Congress' reluctance to pass a Covid funding bill might imperil the U.S. pandemic response just in time for a winter surge. We also chat about the latest news in the life sciences, including Clay Siegall's resignation and Martin Shkreli's release from federal prison.

Is the next Covid surge upon us? How do you make $350,000 a day in biotech? And when did Seagen find out about its CEO's arrest? First, we discuss the latest alarming trends in the Covid-19 pandemic and explaining the curious case of Moderna's briefly employed chief financial officer. Then we pick apart the implications of Pfizer's $11.6 billion acquisition of Biohaven and the struggles of a once-promising idea in cancer immunotherapy. Finally, we examine the arrest of Seagen CEO Clay Siegall and the unanswered questions about the company's response.

Who's going to run Biogen? Does Aduhelm have a future? And is it OK to shame reporters? This week, we delve into Biogen's twin announcements that the company is pulling the plug on Aduhelm and replacing its embattled CEO, discussing the future of Alzheimer's disease and just who might want to lead the company. We also explain the latest on Covid-19 vaccines, a strange situation for Vertex Pharmaceuticals, and the controversy surrounding the White House Correspondents' Dinner.

Can rewired cells cure some patients' cancer? Do biotech stocks ever go up? And why's it taking so long to get kids vaccinated for Covid-19? Immunologist Katy Rezvani of MD Anderson Cancer Center joins us to explain the massive potential of a new approach to treating wily tumors, one that repurposes human immune cells. We also discuss the latest news in the life sciences, including an interesting hire at Novartis, the pediatric Covid-19 vaccine saga, and another negative milestone for biotech.

Can buyouts be bad news? Why can't Novavax meet a deadline? And what does "breakthrough" actually mean? First, we delve into why the latest big biotech acquisition has ominous implications for the downtrodden sector. Then, STAT's Mario Aguilar joins us to explain how a well-intentioned FDA program is benefiting companies over patients. We also discuss the latest pandemic news, including the ongoing debate over boosters and yet another delay for Novavax.

Are we supposed to just get used to superspreader events? What's going with Editas Medicine? And why are people on Twitter so angry?

Leana Wen, an emergency medicine physician and public health professor at George Washington University, joins us to talk about the many complexities of living with Covid-19 and the tricky task of defining "normal" in 2022. We also discuss the latest news in the life sciences, including Editas' new CEO, Aduhelm's future, and the data on Covid-19 vaccines for kids.

What's on tap for Roche and its closely followed cancer immunotherapy? Are we all headed for another jab with a Covid-19 vaccine? And what explains the recent success of Vertex Pharmaceuticals' R&D pipeline?

This week, reporter Andrew Joseph joins us to discuss the FDA and its meeting with outside advisers that considered questions about Covid-19 boosters and the potential for updated vaccines that better match the circulating strains of SARS-CoV-2. We'll also dive into a look at Vertex and hear from its top executives about two experimental, but potentially groundbreaking, treatments for pain and type 1 diabetes. And as we often do, we’ll kick off the podcast with a Chatty Cathy round of hot takes on this week’s news.

As long as there's been a medical system, it's been one that is rife with instances of mistreatment — both on the individual and community levels — that have harmful effects on how Black Americans view the health care system. In the first episode of the new STAT podcast Color Code, host Nick St. Fleur speaks with doctors, researchers, and a patient who are all trying to repair the relationship between Black people and the medical institution.

You can find Color Code on any platform you use to get your podcasts. Episodes are released every other week.

Are Covid-19 vaccines a sustainable business? Was Aduhelm an aberration? And what comes after Omicron?

Senior writer Helen Branswell joins us to discuss the latest twists in the pandemic, including rising case counts, next-generation vaccines, and the latest data from pediatric trials. We also dive into the latest news in the life sciences, including Moderna's grand ambitions, Al Sandrock's new job, and the next big FDA debate.

How should pharma treat Russia? Why can't Congress pass a drug pricing bill? And what does wastewater portend for the pandemic?

First, we discuss the drug industry's response to Russia's invasion of Ukraine, and STAT reporter Isabella Cueto joins us to explain how the war has affected the quietly vibrant Ukrainian biotech industry. Then, STAT Washington correspondent Nicholas Florko calls in to review Congress' years of failure to pass laws on drug pricing and examine whether bipartisan support can ever result in actual legislation. We also run through the latest news in the life sciences, including Ashish Jha's new job, global Covid-19 surges, and a long-delayed manuscript from Biogen.

Can biotech companies age gracefully? Where did Covid-19 come from? And does Theranos make for good television?

We cover all that and more this week. We examine Gilead Sciences' recent struggles and what the company's predicament says about the drug industry. Then, MIT Technology Review reporter Antonio Regalado joins us to discuss his new podcast investigating the origins of Covid-19. We also discuss the latest Theranos trial, playing Elizabeth Holmes on TV, and how we managed to make 200 episodes of this show.

Is "test to treat" too good to be true? Does it really matter who gets credit for CRISPR? And what's the offramp for Covid-19?

We cover all that and more this week. Physician and researcher Kavita Patel joins us to explain why President Biden's plans for Covid-19 — including an ambitious idea to distribute antiviral treatments — might not be so simple. We also discuss some milestone data in the quest to turn CRISPR into medicine and the latest twist in the quest to figure out who invented it.

How many Covid-19 vaccines does the world really need? What will it take to address inequality in American health care? And should people be nicer to Moderna?

First, we discuss the latest news in Covid-19 vaccines, including data from Sanofi and GlaxoSmithKline, the future of Novavax, and what comes next for Moderna. Then, STAT’s Usha Lee McFarling joins us to talk about a groundbreaking investigation into racial and ethnic disparities in American medicine — and why almost nothing has changed in the 20 years since it was published.

Will there be a new ALS drug this year? What business does Wall Street have with CRISPR? And when can kids get Covid-19 vaccines?

We cover all that and more this week. First, STAT's Nicholas Florko joins us to preview the trials ahead for Robert Califf as he retakes the reins at the FDA — including a high-profile decision on a new treatment for ALS. Then, CRISPR pioneer Jennifer Doudna and financier Marty Chavez join us to talk about the future of genome editing and the investments they plan to make in it. We also discuss the latest on Eric Lander, the Covid-19 vaccine meeting that wasn't, and the future of Chinese-developed cancer drugs.

Does Big Science have a bullying problem? Why did the FDA change its tune on China? And what's cooler than $100 billion?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. We discuss the scandalous end of Eric Lander's tenure as presidential science adviser with STAT Washington correspondent Lev Facher and science writer Megan Molteni. Then we dive into the FDA's about-face on cancer drugs developed in China and what it means for the cost of medicine in the U.S. We also explain how Pfizer's record-setting year somehow disappointed Wall Street and explore whether it's a good idea to end mask mandates.

Does President Biden care about the FDA? What can aerobics instructors teach us about genetics? And when can kids get Covid-19 vaccines?

STAT Washington correspondent Nicholas Florko joins us to chat about why Robert Califf, once a shoo-in to be the next FDA commissioner, is suddenly in serious jeopardy. Then, we examine one of the coolest drug-discovery stories in medicine with Merck’s head of research, Dean Li, who joins us to talk about the company’s efforts to develop an oral cholesterol pill targeting PCSK9.

Who gets to be an "expert" on Covid-19? Are Americans entitled to drugs that don't work? And how does the FDA deal with states' rights?

First, we discuss the FDA's decision to halt the use of two Covid-19 antibodies that don't work against Omicron — and the surprising backlash that ensued. Then, acting FDA commissioner Janet Woodcock joins us to dig into the agency's move and discuss the steps for regulation of Covid drugs. We also go over the latest news in the life sciences, including some bad news for Gilead Sciences and a rare victory for a small biotech company.

With biotech in the dumps, we talk to Oppenheimer analyst Jared Holz about why the world has soured on the sector and what it means for the future of medicine. Then, STAT’s Matthew Herper joins us to explain the latest big idea from biotech's big thinkers: a company called Altos Labs, which has raised $3 billion to do something or other. We also discuss the latest news in the life sciences, with a cameo from Shkreli and an update on Omicron.

First, STAT health tech correspondent Katie Palmer joins us to recap the J.P. Morgan Healthcare Conference. Then, we discuss the latest twist in Biogen's quest to expand the use of Aduhelm and what it means for the treatment of Alzheimer's disease. Finally, Arrakis Therapeutics CEO Michael Gilman calls in to explain how targeting RNA can treat disease and why the characters in "Dune" don't just shoot each other with laser guns.

First, emergency room physician Craig Spencer joins us to talk about how the Omicron variant is impacting New York City and what the coming months have in store. Then, we look ahead to the New Year in biotech with a preview of the J.P. Morgan Healthcare Conference. We start with a look at the latest news in the life sciences, including Elizabeth Holmes' guilty verdict and the ongoing Aduhelm saga.

We've come to our last episode of the year, and first, STAT’s Helen Branswell joins us to talk about Omicron, boosters, and the past and future of the Covid-19 pandemic. Then, we'll review the year that was in biotech, discuss the suddenly virtual J.P. Morgan Healthcare Conference, and look forward to 2022.

On this week's episode, we kick off the conversation with an update on what researchers are discovering about the Omicron variant of the coronavirus, including new findings from a study involving the Pfizer Covid vaccine. Then, we'll shift the talk to this week's blockbuster STAT story about Biogen and the all the behind-the-scenes turmoil caused by its controversial treatment for Alzheimer's.

Will the first Covid-19 pill be all that useful? How worrisome is Omicron? And when will it be safe to congregate?

First, STAT's Matthew Herper joins us to talk about a tense debate among FDA advisers about molnupiravir, a Merck treatment for Covid-19 whose luster has faded over time. Then, we talk to Emory University’s Carlos del Rio about the potential of Pfizer’s antiviral pill, the future treatment landscape for Covid-19, and how the emerging Omicron variant might change the global pandemic response.

First, epidemiologist Michael Osterholm of the University of Minnesota joins us to talk about Covid-19 case counts, vaccination rates, and the state of the pandemic as we head into the holidays. Then, we discuss the surprising news that Al Sandrock, Biogen’s long-time chief scientist, is leaving the company after a tumultuous year.

Rebecca Robbins of the New York Times joins us to discuss the escalating tension between Moderna and the National Institutes of Health over just who invented a Covid-19 vaccine. Then, STAT's Olivia Goldhill calls in to explain Compass Pathways' promising results using psilocybin as a treatment for depression and the future of the nascent field of psychedelic medicines. We also discuss the latest news in the life sciences, including pills for Covid-19, the next FDA commissioner, and whether Pfizer CEO Albert Bourla listens to Joe Rogan.

STAT's Rachel Cohrs drops in to talk about the latest updates in drug pricing reform. Then, John Maraganore joins us to talk about his decision to step down as CEO of Alnylam Pharmaceuticals after almost 20 years with the company. We also discuss the latest news in biotech, including the Covid-19 vaccine for kids and Moderna's disappointing earnings call.

Can the FDA be too transparent? Who deserves credit for Operation Warp Speed? And when is a CEO worth $3 billion? We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. STAT's Helen Branswell joins us to discuss the whirlwind of FDA debates around who should get vaccines for Covid-19 and the coming months of pandemic response. Then, Brendan Borrell calls in to talk about his book, "The First Shots," a behind-the-scenes look at Operation Warp Speed and the race to develop those vaccines. We also discuss the surprise announcement that longtime Alynlam Pharmaceuticals CEO John Maraganore is soon to leave the company.

Wall Street Journal reporter Gregory Zuckerman joins us to share some behind-the-scenes details from race to develop a Covid-19 vaccine, the subject of his new book. We also discuss the latest news in the life sciences, including Biogen’s failure to launch, the plight of a Covid pill, and a headline-grabbing statement from one of biotech’s most famous scientists.

STAT Washington correspondent Nicholas Florko joins us to provide an inside look at the eleventh-hour search for a permanent FDA commissioner. We also discuss the latest twist in the debate over Covid-19 vaccine boosters, some upheaval in the world of genome editing, and a little news for parents from one Scott Gottlieb.

First, we discuss the scramble to find new leaders for the NIH and FDA, the latest online dustup involving Ginkgo Bioworks, and the growing promise of antiviral treatments for Covid-19. Then, filmmaker Brent Hodge joins us to discuss his documentary "Pharma Bro," which chronicles the trial, conviction, and prolific livestreaming of one Martin Shkreli.

First, we welcome STAT reporter Usha Lee McFarling onto the podcast to discuss her investigation into health equity tourism — how white scholars are colonizing research on health disparities. Then, we "chatty Cathy" a blizzard of biotech news from this week, including Merck's $11 billion acquisition of Acceleron Pharma, a theatrical street protest about the Covid vaccine equity dive, a debate about gene therapy's future, and, finally, why Scott Gottlieb is looking up at Elvira.

First, STAT's Helen Branswell joins us to discuss the state of the Covid-19 pandemic as we head into another winter. Then, former FDA Commissioner Scott Gottlieb calls in to discuss his new book on how the U.S. got caught off guard and what the government needs to do before the next pandemic hits. We start with a look at the latest news in the life sciences, including the booster debate, Biogen's trouble selling its controversial Alzheimer's drug, and the awkward pairing of beer and face masks.

Can prosthetic limbs feel real? Is the FDA softening under pressure? And are Rice Krispies Treats admissible in court?

STAT's Gideon Gil joins us to share the remarkable story of an amputation surgery that makes a phantom limbs feel like the real thing. Then we discuss the FDA's surprising reversal on a new treatment for ALS and whether it signals a sea change within the agency. We start with a look at the latest news in the life sciences, including the debate over Covid-19 vaccine boosters, the future of in-person conferences, and a mysterious sweet-toothed observer at Elizabeth Holmes's fraud trial.

First, STAT's Erin Brodwin joins us to talk about Verily, Google's big-idea life sciences company that is now under pressure to produce some actual products. Then, health care investor Bijan Salehizadeh calls in to discuss the dearth of rapid Covid-19 tests in the U.S. and how industry, regulators, and lawmakers share the blame. We also take a look at the latest news in biotech, including Biogen's troubled launch of Aduhelm, Moderna's long-term scientific ambitions, and a big day for the Waksal brothers.

Former Theranos CEO Elizabeth Holmes is finally headed to trial, and we discuss the case and why it might not be an open-and-shut conviction for prosecutors. Then, STAT Washington correspondent Nicholas Florko joins us to explain the latest upheaval at the FDA, which arrives just as the agency faces mounting pressure to speed up the review of Covid-19 vaccines. We also discuss the race to develop antivirals for SARS-CoV-2 and why the eyelash-growth business is booming.

First, law professor Dorit Reiss joins us to discuss what the first FDA approval of a Covid-19 vaccine means for vaccination mandates and how this whole issue relates to jaywalking. Then we discuss biotech's messy summer, which has brought allegations of data manipulation, sloppy clinical development, and questionable transparency. We also run through the latest news in the life sciences, including the evolving booster shot debate and a Netflix film about the perils of pharmaceutical greed.

First, we discuss a sudden spike of FDA rejections, which has resurfaced a time-honored frustration: You can’t always trust biotech companies to be honest about their conversations with the agency. Then, STAT's Lev Facher joins us to share his reporting from Louisiana, where a surge of Covid-19 deaths among the unvaccinated is having devastating effects on health workers. Before that, we talk about a curious case of alleged insider trading, medical conferences in the time of Delta, and the global vaccine push.

First, STAT Washington correspondent Nicholas Florko joins us to explain President Biden's proposal to lower drug prices, how it might affect the 2022 election, and why there's still no nominee for FDA commissioner. Then, Shraddha Chakradhar calls in to look back on her time running STAT’s flagship newsletter, Morning Rounds. We also discuss the rise of Covid-19 mandates, Canada's biotech ambitions, and Wall Street's exuberance over new treatments for Alzheimer's disease.

First, we dive into the potential of mRNA, a technology that proved itself with Covid-19 vaccines and is now seeding a pharmaceutical gold rush. Then, STAT's Helen Branswell joins us to discuss the state of the pandemic, the implications of the Delta variant, and the debate around booster shots. We also dissect the week's news in biotech, included Amgen's tax problems, a meltdown in synthetic biology, and the latest on Aduhelm.

First, we discuss the CDC's about-face on mask wearing, the debate over vaccine booster shots, and the slow but steady race to develop pills for Covid-19. Then, STAT's Kate Sheridan joins us to discuss a setback in the field of microbiomics and the mounting skepticism over whether tinkering with gut bacteria can eventually treat a host of diseases. We also break down the latest fallout from the FDA's approval of Aduhelm, the sorry state of biotech stocks, and an in-development feature film about CRISPR.

First, Céline Gounder of NYU’s Grossman School of Medicine joins us to discuss the issue of breakthrough coronavirus infections and whether the U.S. was too quick to unmask. Then, STAT's Rachel Cohrs calls in to share the curious case of the moderate Democrat who made thousands of dollars in pharma donations within two days of attacking a drug pricing bill. We also discuss Biogen's latest defense of Aduhelm, the debate over Johnson & Johnson's Covid-19 vaccine, and the latest movie casting Big Pharma as a villain.

First, we'll talk about the future of the FDA, whose acting commissioner will have to step down in November unless she’s given the permanent job. Next, Washington Post reporter Dan Diamond joins us to discuss the politics of the vaccine rollout and how covering this administration differs from writing about the last one. Plus we break down the latest news on Covid-19 and the continued Aduhelm fallout.

First, we discuss the latest twists following the FDA's widely condemned decision to approve Aduhelm, Biogen's treatment for Alzheimer's disease. Then, our STAT colleague Helen Branswell joins us to talk about whether viral variants are going to stymie the U.S.'s summer reopening. Finally, STAT's Mario Aguilar calls in to break down the record-setting sums going into digital health companies in 2021.

First we talk to George Yancopoulos, head scientist at Regeneron Pharmaceuticals, about the future of CRISPR genome editing and the latest idea for treating obesity. Then, we discuss STAT's reporting on the cozy relationship between Biogen and the FDA ahead of Aduhelm's approval and what the ensuing fallout might mean. Before all that, we chat about the latest news in biotech, including vaccine boosters and a decadelong debacle.

First, we sift through the week's news, with a major update from Eli Lilly in Alzheimer's disease and new details on the inner workings of the FDA. Then, STAT's Matthew Herper joins us to discuss how GlaxoSmithKline ended up in a self-preservation struggle. Finally, STAT's Nicholas St. Fleur calls in to talk about the alarming rise of colorectal cancer deaths among young men and his decision to get on an on-camera colonoscopy for a reporting project.

First, we sift through the week's news, with some disappointing Covid-19 vaccine data, a pair of setbacks for biotech, and the Wall Street debut of 23andMe. Then, vaccinologist Paul Offit joins us to explain the scientific debate over whether we'll need booster vaccine doses to stay protected from SARS-CoV-2. Finally, Truist Securities analyst Robyn Karnauskas calls in to talk about her bold 2020 prediction that Biogen's controversial treatment for Alzheimer's disease would eventually win FDA approval.

We're devoting this entire episode to the FDA's polarizing decision to approve Aduhelm, a controversial Biogen treatment for Alzheimer's disease. First, we'll break down what happened and why it's such a big deal, and then we'll talk about the broader implications for science, medicine, and the drug industry as a whole. Finally, we'll zoom out explore how the FDA got to this moment in a conversation with Yale University professor and global health activist Gregg Gonsalves.

First, we discuss why it's so hard to predict FDA decisions, and why the latest big deal in biotech left investors cold. Then, STAT Washington correspondent Nicholas Florko joins us for a dive into the thousands of emails from Anthony Fauci made public this week, complete with a top-five countdown of messages both impactful and absurd. Finally, longtime Associated Press medical reporter Marilynn Marchione retired last week, and she calls in to talk about the biggest stories of her career.

STAT's Andrew Joseph joins us to talk about the two-year anniversary of the approval of gene therapy Zolgensma and the effect it has had on families dealing with the rare disease spinal muscular atrophy. Then, former FDA Commissioner Scott Gottlieb calls in with tips on Memorial Day grilling, notes on a recent Twitter spat, and thoughts on the origins of SARS-CoV-2.

First, we discuss Ginkgo Bioworks, the multibillion-dollar biotech company with grand ambitions, a famous ticker symbol, and an affinity for memes. Then, STAT’s Helen Branswell joins us to discuss a topic on everyone’s mind: How will the Covid-19 pandemic end? Finally, we’ll talk about the modern phenomenon of the pandemic celebrity and the case of Ashish Jha, TV’s ever-present Covid-19 expert.

Can we prevent the next Covid-19? Has the CDC become too cautious? And how many sensors should be worn to bed? First, our colleague Helen Branswell joins us to discuss where the world went wrong with Covid-19 and how to prepare for the next pandemic. Next, STAT D.C. correspondent Nicholas Florko calls in to talk about the public health experts who believe the Centers for Disease Control and Prevention has been too sluggish and conservative in recent months. Finally, our colleague Nick St. Fleur joins to recap this week’s STAT Health Tech Summit, which featured some boisterous CEOs, ambitious startups, and promising technologies.

First, Moderna and Pfizer are poised to make billions of dollars from their Covid-19 vaccines this year, and we discuss what that massive infusion of cash portends for both companies. Next, Thomas Bollyky of the Council on Foreign Relations joins us to explain what the U.S.'s support for waiving Covid-19 vaccine patents means — and doesn’t mean — for the global vaccination effort. Finally, STAT’s Megan Molteni calls in to share the story of a little-known biotech company recruiting patients to Mexico with the promise of an anti-aging gene therapy in an unregulated clinical trial.

First, STAT Washington correspondent Rachel Cohrs joins us to explain why President Biden's endorsement for drug pricing reform rang hollow to many advocates. Next, virologist Angela Rasmussen calls in to discuss the controversy around a Russian-produced vaccine for Covid-19. Finally, STAT's Kate Sheridan joins us to talk about how a shortage of cheap, little-discussed plastic tools is hobbling scientific labs around the world.

First, Northwestern University epidemiologist Mercedes Carnethon joins us to weigh on the nation's latest Covid-19 debate: Is it OK to go maskless outdoors? Then, STAT Washington correspondent Nicholas Florko calls in to talk about why the Biden administration is waiting so long to nominate an FDA commissioner and how that indecision could have real consequences. Later, we discuss the scientific promise of novel treatments for sickle cell disease — and the industry's growing concern that they might not be as lucrative as once thought. And, naturally, we recap the latest news in the Covid-19 vaccine rollout.

How do you describe a one-in-a-million risk? What's heparin-induced thrombocytopenia? And why's it so hard to find drugs for Covid-19?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. First, Science Magazine reporter Kai Kupferschmidt joins us to discuss the U.S. decision to press pause on the Johnson & Johnson vaccine and what researchers have learned about rare cases of dangerous clotting. Then, biotech analyst Josh Schimmer joins us to talk about why the drug industry has had such a hard time coming up with treatments for Covid-19 and offer some tips that might help in the next pandemic.

What's next for AstraZeneca? Are there any right answers when it comes to compassionate use? And how does it feel to give someone a Covid-19 vaccine?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. First, we discuss the latest in a long series of issues for AstraZeneca’s Covid-19 vaccine and the implications for the global pandemic response. Next, we dive into the dilemma over compassionate use, talking to Biogen's former PR chief about the struggle over whether — and how — desperate patients should be able to access experimental medicines. Finally, we interview a registered nurse in Boston about what it's like to bring joy, relief, and reassurance to thousands of people by injecting them with Covid-19 vaccines.

First, STAT’s Mario Aguilar joins us to discuss a fascinating experiment in Nevada, where one city is giving its residents free access to a therapy app — and getting a mixed reception. Then, New York University antitrust expert Eleanor Fox calls in to discuss the case of Illumina, the genome sequencing giant whose grand plans keeping running afoul of the Federal Trade Commission. Finally, we embark on a lightning round, covering the latest Covid-19 vaccine news, biotech’s biggest events over the next three months, and the death of a pioneering Gilead Sciences executive.

We're devoting this week's episode to the week of whiplash news about AstraZeneca's Covid-19 vaccine, subject of a baffling international incident with consequences still unfolding. First, we explain the series of late-night announcements that made global headlines. Then, our STAT colleague Helen Branswell joins us to discuss the implications for AstraZeneca, vaccine confidence, and the global effort to get doses in arms. Finally, STAT's Matthew Herper calls in to talk about Pascal Soriot, the hard-charging AstraZeneca CEO whose previously feted boldness might have backfired when it came to Covid-19.

First we unpack the crisis of confidence facing AstraZeneca's Covid-19 vaccine in Europe with Alison Buttenheim, a University Pennsylvania professor who studies vaccine acceptance. Then, we explain the latest data on an Alzheimer's disease treatment from Eli Lilly and why it has polarized experts in the field. Finally, we make a modest proposal to the biotech industry: Give honesty a chance.

We're joined by Natasha Loder, the health policy editor at The Economist — and a London resident — to get her home-country perspective on the U.K.'s Covid vaccine development efforts. Next, we'll talk with STAT national technology correspondent Casey Ross about his yearslong investigation into the demise of Watson Health, IBM's AI health care initiative. Finally, STAT's Meghana Keshavan joins us for a primer into synthetic biology, including its role in making the mRNA-based Covid vaccines.

We discuss Merck's decision to help Johnson & Johnson manufacture vaccine doses and whether it'll be a turning point for the drug industry or a relic of Covid-19 history. Then, as we near the one-year anniversary of the pandemic, STAT's Andrew Joseph joins us to explain what experts think is in store in the months and years to come. Finally, Ashish Jha, dean of Brown University’s School of Public Health, joins us to explain why he's optimistic about summer 2021.

First, pediatric cancer advocate Nancy Goodman joins us to discuss why she believes Covid-19 vaccine trials need to be sped up for teens and children. Then, Wall Street Journal reporter Greg Zuckerman calls in to explain the unlikely story behind Novavax, a former biotech penny stock now on the verge of making history. Finally, we embark on a lightning round, featuring quick takes on the confirmation process for a new health secretary and the future of therapeutic stool.

We discuss all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. First, we break down a significant setback for Bluebird Bio’s gene therapy program with some help from Akshay Sharma, a bone marrow transplant expert at St. Jude Children’s Research Hospital. Then, STAT's Kate Sheridan joins us to discuss her deep dive into Flagship Pioneering, the superlatively successful and frequently grandiose venture firm behind Moderna. Finally, we dig into what the future might hold for a post-Trump FDA, which remains without a permanent commissioner.

When will we have enough vaccine doses? How many effective Covid-19 drugs are just waiting to be found? And what do Redditors think about biotech? We discuss all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. First, we check in with our colleague Helen Branswell for her view on the current state of the Covid-19 pandemic and the ongoing vaccine rollout. Then, we're joined by David Fajgenbaum, a physician and scientist at the University of Pennsylvania, to talk about his work to identify and develop treatments for people with Covid-19. Lastly, we embark on a lightning round, covering Gilead Sciences' latest setback, a schism in Alzheimer's disease research, and a preview of the newest podcast from STAT.

We discuss all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. First, we recap a busy week of news, featuring 23andMe's move to go public through a blank-check company, Merck CEO Ken Frazier's retirement after three decades at the drug maker, and how the future of Biogen’s Alzheimer’s disease drug got a little more complicated. Then, Paul Offit, director of the Vaccine Education Center at the Children’s Hospital of Philadelphia, joins us to weigh in on the bounty of recent Covid-19 vaccine data from Johnson & Johnson, Novavax, and AstraZeneca. Finally, STAT's Casey Ross calls in to discuss his investigation into the FDA's chaotic approach to approving medical products that use artificial intelligence.

First, we discuss the implications of Johnson & Johnson’s any-day-now data on a one-shot vaccine for Covid-19. Then, Kevin Davies, executive editor of the CRISPR Journal, joins us to talk about the strange boom in genome editing stocks and the future of the revolutionary technology. Finally, we talk to Megan Ranney, an emergency room physician and Brown University professor, about the challenges of Covid-19 science communication in a post-Trump world.

We're spending this entire episode remembering Sharon Begley, our revered and beloved colleague who died last week from complications of lung cancer. First, STAT's Eric Boodman joins us to discuss Sharon's path-breaking career and what he learned from reporting out her obituary. Then, a trio of STAT editors call in to talk about what it was like to work with Sharon, and we hear from number of her colleagues about what made her a singular writer, mentor, officemate, and friend.

We're devoting this episode to the news coming out of the just-concluded J.P. Morgan Healthcare Conference, the drug industry's largest annual meeting. First, we'll dissect Eli Lilly's surprising data on a new Alzheimer's disease treatment and dig into its implications for the field. Then, we discuss whether there's a bubble inflating in the genome editing world, debate who will run the FDA under a President Biden, and consider the legacy of Moncef Slaoui, the outgoing leader of Operation Warp Speed.

On this year's first episode, STAT Washington correspondent Lev Facher joins us to break down the implications of a Democrat-controlled Senate. Then, our colleague Erin Brodwin calls in to talk about CES, the massive tech conference taking place next week. Finally, we chat with Bob Nelsen, a biotech venture capitalist and one of the few people who saw the coming pandemic with clarity months before everyone else, about what's ahead in 2021.

It's the final episode of 2020. We dig into the second vaccine that's been recommended by a panel of FDA advisors, and look ahead to see what's in store for biotech in 2021.

Are Covid-19 vaccines safe for teens? Is the U.S. taking too long to authorize one? And how do you prepare for an FDA grilling?

Can too much Covid-19 vaccine be a bad thing? Is biotech in a bubble? And how do you make blind mice see again?

How do we measure whether Covid-19 vaccines work? What does Joe Biden think of the drug industry? And does Anthony Fauci think about retirement?

How well does Pfizer's Covid-19 vaccine work? What's the difference between efficacy and effectiveness? And should the FDA approve Biogen's Alzheimer's drug?

How bad will this winter be? Is everything coming up Biogen? And who's going to be president on Jan. 20? We discuss all that and more on this week's episode of “The Readout LOUD,” STAT's biotech podcast. First, STAT's Helen Branswell joins us to discuss what the winter has in store for the ongoing Covid-19 pandemic. Then, we discuss the latest surprising twist in Biogen’s quest to win FDA approval for a polarizing treatment for Alzheimer’s disease. Finally, STAT reporter Casey Ross joins to talk about the recent death and legacy of Bertrand Might, a 12-year boy born with a rare genetic disease.

When are we getting Covid-19 vaccine data? Will concerts ever be safe again? And what's a "Bionomy"?

Who's voice rings loudest at the FDA? Is it wise to give hedge funds a blank check? And how will the Biogen saga end?

Is your local lawmaker flush with pharma cash? How does racism in medicine loom over Covid-19 studies? And who decides when a clinical trial goes on pause?

Why is the president making drug ads? Are antibodies the new vaccines? And is it ethical for doctors to talk about President Trump's health?

Can an itchy arm ruin a clinical trial? Does intermittent fasting work? And is pharma more trustworthy than the CDC?

Is superspreading an Olympic event? Will Covid-19 forever change health tech? And what are the limits of Anthony Fauci's patience?

How should governments talk about Covid-19? Can the Centers for Disease Control and Prevention rebuild public trust? And when is a steak worth $21 billion?

Is AstraZeneca’s Covid-19 vaccine in jeopardy? Why can’t politicians and scientists in Washington get along? Did you miss STAT’s first-ever Health Tech Summit?

Should the FDA commissioner resign? How fast can vaccine trials move? And what do Chelsea Clinton and Chuck Grassley have in common?

Can the Food and Drug Administration survive Trump? Are drug reviewers in the deep state? And what can Elon Musk teach us about the nature of reality?

Did the FDA suddenly get stringent about new drugs? Is longevity research over-hyped? And what can recovered patients teach us about Covid-19 vaccines?

Is pharma scared of Kamala Harris? Are there second acts in biotech? And why don't Covid-19 trials look more diverse?

Does the future of health tech look like Facebook? Can we cut corners with Covid-19 vaccines? And are journalists slowing down Operation Warp Speed?

How much should a Covid-19 vaccine cost? What can basketball teach us about pandemic safety? And just how lucrative is venture capital?

How soon will we get a Covid-19 vaccine? Why is biotech moving airline stocks? And what can we learn from 1860s science?

What do we want from a coronavirus vaccine? Can the U.S.’s Covid-19 response be saved? And how can the field of medicine address structural racism?

Who will stand up to the White House? How can hospitals protect workers from Covid-19? And what ever happened with Biogen?

What’s a fair price for remdesivir? How do we know whether vaccines work? And does AI have a place in end-of-life care?

Is this a second wave or a rising tide? Who’s the real GlaxoSmithKline whistleblower? And what happens to cancer care in a pandemic?

Can a vaccine be an October surprise? Are journal publishers running a racket? And why is genetics so white?

Can a virtual conference feel real? Do scientists have a say in their benefactors' business? And what does it take to get remdesivir in the U.S.?

The killing of George Floyd at the hands of a white Minneapolis police officer has brutally underlined the systemic racism that informs policing, housing, education, and health care in the U.S. This podcast covers the world of biotech, which, like every facet of our society, is affected by racism and inequality. So, first, we talk about how the drug industry has responded to Floyd’s killing and what that response means. Then, we're joined for a conversation with longtime biotech executive Tony Coles, who is also a founding member of the Black Economic Alliance, a group of business leaders who raise money for candidates and causes. We talk about why Floyd's killing sparked global action, the relative value of public statements, and what business leaders can do to combat racism.

What happens after we get a coronavirus vaccine? Can virtual medical meetings replace the real thing? And wasn’t Amazon supposed to disrupt health care?

When is a press release worth $5 billion? Can biotech stocks replace sports? And how will we know if a coronavirus vaccine actually works?

What can the adult film industry teach us about fighting coronavirus? Does the FDA approve Zoom backgrounds? And is it ethical to fund a study of yourself?

What if the curve just stays flat? How much should a Covid-19 drug cost? And what's it like on the ground in the epicenter of the novel coronavirus?

Just how well does Gilead Sciences' Covid-19 drug work? Is politics getting in the way of public health? And who gets the eventual coronavirus vaccine first?

Why was the infectious disease community in denial about the unfolding pandemic? When can we expect a vaccine? And are ventilators being overused?

What's the proper distance to stand from Sen. Mitch McConnell? How many PowerPoint charts is too many? And when will Theranos get its day in court?

Can the drug industry win over Americans? Will the pandemic put an end to privacy? And could Martin Shkreli save the world?

When will things go back to normal? What if a pandemic strikes when you're already sick? And what does Ken Burns know about genomics?

When can we stop distancing? Does the "deep state" meet over Zoom? And could the amyloid hypothesis come through at last?

Why did the U.S. change its tune on coronavirus? What's it like to be an ICU nurse right now? And when are we getting a vaccine?

How long will this pandemic persist? Are U.S. hospitals going to be overwhelmed? And what’s it like to be quarantined on a cruise ship?

Does “The Art of the Deal” cover vaccines? Is patient privacy a relic of the past? And how big can biotech get in China?

Is the market overreacting to the coronavirus? Why do so many clinical trials go unfilled? And how do you pronounce "Martin Shkreli"?

Can biopharma police itself? Who decides whether something's a disease or a difference? And will fecal matter ever become a drug?

What's the right way to give drugs away? Is $3 billion even a lot of money? And when is biotech hype justified?

Is peer review underrated? Can biotech stop an outbreak? And would you mind giving us a call?

We're coming up on the 100th episode of this podcast, and we're using the occasion to actualize our long-held dream of running a call-in show. Dial us at 617-517-6130 and leave a message with any question you'd like us to answer on the podcast, and you may just hear it on air in the coming weeks.

Is it wise to lie to the feds? Is pharma taking Sen. Bernie Sanders seriously? And what constitutes a "public health emergency of international concern?"

Are we dealing with a SARS redux? Has the FDA lost its teeth? And what do billionaires talk to each other about?

Why weren't there any big deals announced this week? What does the word "equivalar" mean? And why is information about prognosis so hard to find?

Does pharma deserve more credit? Will history forgive He Jiankui? And how does a laboratory eureka become a lifesaving vaccine?

Which drug defined the decade? Who's the worst CEO in biopharma? And how does gene therapy actually work?

Has CAR-T lost its luster? Why is colorectal cancer on the rise? And did the FDA forever change in 2016?

How do you know if a "positive" study is positive? And how did one-eyed sheep lead to a drug for certain cancers?

Can Sen. Elizabeth Warren ever go home again? Is it ethical to make little people taller? And when will AI come up with a new drug?

Do you trust Google with your health data? Is "Gattaca" an outdated reference? And what's it like to get dunked on?

Why hope for China's new Alzheimer's drug turned into skepticism ? Is three a crowd in CAR-T? And what's a Bionomy?

When should a drug be pulled from shelves? How do you pronounce "HLTH?" And how does Ann Coulter decide what to tweet?

What exactly is Biogen doing? When is a press release worth $12 billion? And what should patients make of whiplashing news? We're devoting this entire episode to Biogen's stunning announcement that aducanumab, its once-discarded treatment for Alzheimer's disease, is getting a second life.

Should drug companies be free-speech advocates? Is your retirement dependent on CRISPR? And how useful is a glow-in-the-dark dog?

STAT's Matthew Herper joins us to dig into the history of the infamous pain drug Vioxx and a new effort to bring it back as a rare disease treatment. Then, we discuss how the synthetic biology industry is growing up and getting corporate. Finally, health care journalist Maggie Fox dials in to explain her deep dive on venture capital in biotech.

Does impeachment have a pharma angle? Who's to blame for drug shortages? And why is Wall Street down on biotech?

What do we talk about when we talk about "vape"? Are there limits to business of DNA testing? And how hard is it to get yourself CRISPR'd?

STAT's Megan Thielking joins the gang to break down a major week of news in the world of vaping and STAT's Sharon Begley relates the story of a desperate patient seeking off-the-books genome editing and its implications for the future of medical research.

Who puts horns on unicorns? How do graying drug companies find green ideas? And what would mice tweet?

House Speaker Nancy Pelosi’s drug pricing plan is aggressive, but is it viable? Can Moderna turn cells into tiny drug-making factories? What’s it like to cure your own rare disease?

What separates good drug companies from mediocre ones? Have biohackers sold out? And who's going to run the FDA?

What does Dr. Richard Sackler sound like? When is $500 million a small amount of money? And what will come of the drug companies at the heart of the opioid crisis?

How should you talk to friends about rejection? Can Facebook actually improve the lives of children? And how's biotech doing in China?

Is anything too weighty to be explained over the internet? Can a new spin on old technology outfox CAR-T? And does that controversial drug even work?

Why did Novartis (NVS) keep its scandal to itself? Who knew what and when? And is there such thing as too much Peloton time?

Will Canada run out of drugs? Should you ever read your partner's diary? And what does Pepe the Frog know about genomics?

What makes an epidemic newsworthy? Can biotech succession succeed? And what's so novel about digital health?

Can apps treat anxiety? Is Gilead Sciences back on track? And are we all just brains in a vat?

Is drug pricing too complex for the Trump administration? Would you recognize Tom Hanks at a party? And what does it mean when famous executives quit?

Can Botox make Big Pharma attractive? What qualifies as a "cabal"? And will the CRISPR patent fight outlive us all?

Is desire a matter of medicine? Can you convict on genealogy? And what do you get the alleged bride who has it all?

Is biohacking a crime? Who came up with the latest CRISPR trick? And did Rage Against the Machine sell out?

Who won ASCO? Is pharma sandbagging its blockbusters? And what do gladiators have to do with biotech?

What can be done to improve HPV vaccination rates in the U.S.? How does the genetic signature of a tumor lead to an effective cancer drug? What’s it like being a doctor and a cancer patient?

Who's guilty of "clickbait"? Are spit tubes a bad business? And why are academics emulating Pusha T?

What should you watch for at the year's biggest cancer conference? Why are people having 23andMe-induced identity crises? And what's it like to be at once a journalist and a cancer patient?

Has drug price reform already stalled? How far has tech come in medicine? And should there be an app for that?

Are law-breaking pharma executives the new mob bosses? Can genome editing preventing heart attacks? And can the FDA regulate drug prices?

Is Biogen bracing for a fight? What does Jack Daniels have to do with immunotherapy? And will "micro-dosing" light the way to actual therapies?

Who gets to be "influential"? Should you be skeptical of for-profit hospitals? And should George Lucas fire his attorneys?

Who gets to "play God"? Can old technologies learn new tricks? And what does "drug price" even mean?

How do you sell lefty ideas to righty politicians? What’s going on at Gilead Sciences? And why are biotech investors freaking out?

What if pharma just charged less for drugs? Can speaking three syllables reveal whether you're depressed? And why is Snoop Dogg selling erectile dysfunction pills on TV?

Why can't investors think for themselves? How do parents cope with inexplicable tragedy? And is tech prepared for the toughest parts of health care?

Should Alzheimer's researchers just give up on amyloid plaques? What will a new drug mean for new moms with postpartum depression? And which coastal region of Long Island is superior?

Who deserves credit for a new gene therapy? How do you push stop on a startup? And what does MC Hammer have to do with Theranos?

Why is Scott Gottlieb quitting the FDA? Who will replace him? And what's the proper elastane content of a skinny jean?

Is this the age of the big biotech buyout? Is cold brew a business expense? And how do you pronounce "Gonzalez"?

What did an opioid patriarch say under oath? Why did everyone want to know so badly? And how might it shape the conversation around the opioid crisis?

Is pharma about to have its Big Tobacco moment? Are we overestimating human genetics? And can sales reps rap?

We discuss all that and more on the latest episode of “The Readout LOUD,” STAT’s biotech podcast. First, Boston Globe reporter Jonathan Saltzman joins us to discuss the case against Insys Therapeutics, the maker of a powerful painkiller now accused of running a nationwide racketeering scheme. Then Dr. Laura Esserman of the University of California, San Francisco, comes on to break down the debate over genetic testing for cancer risk. And then we give you the need-to-know on an upcoming Senate hearing that will see seven pharma executives get grilled on the rising cost of medicines in the U.S.

When will AI replace your radiologist? What can pharma learn from ketamine? And is liver disease more complicated than anyone thought?

Are we underestimating biology? Will Hot 97 decide the presidency? And who owns the scientific means of production?

Is the drug industry wrong about Alzheimer's disease? Can cryptocurrency fund actual science? And should you feel sorry for Big Pharma?

Is genome editing harder than anyone thought? Will no one weep for Celgene? And is it time to sequence your dog?

Is the FDA going broke? Can video games be drugs? And when did "Flashdance" come out?

Do drug developers tip well? Is biotech safe for 6-year-olds? And what's a Cable Car Cosmo?

Are megamergers bad for business? Is it time for biotech's biggest gathering to find a new home? And can a "need" be anything but "unmet"?

What will become of biotech in 2019? What's the legacy of Sarepta Therapeutics? And how do you say "overhyped" in Mandarin?

Is Gilead Sciences entering a bold new era? What even happened in 2018? And how useful is a genetic credit score?

Can gene therapy cure sickle cell disease? Is an expensive drug better than a free one? And will biotech see its shadow in 2019?

What does it mean to edit a person? Has science run afoul of basic ethics? And what's the time difference to Hong Kong?

Can unicorns float? Is a hot dog a sandwich? And how are drug companies like gas stations?

Is pharma in for a swarm of subpoenas? Are we running out of ideas in oncology? And can a drug possibly be worth $4 million a dose?

Why are biotech stocks in the dumps? Is the latest in cancer care overhyped? And what does "folie à deux" mean?

Can pharma-shaming get someone re-elected? How rare is too rare when it comes to biotech research? And what does "positive" even mean, really?

Are prescription drugs like new cars? Is pharma's grand bargain a sham? And who keeps your DNA safe?

Is the next big idea in oncology a bust? What does "successful" mean exactly? And why does Wall Street hate biotech all of a sudden?

Did the Nobel Prizes go to the right scientists? Why is there so much disdain for biotech's millenial entrepreneurs? And do journalists have a good taste in '80s music?

Was everyone wrong about fish oil? Is venture capital a cartel? And what's with all those ketamine clinics?

Is a biotech bubble inflating in China? Do the feds coddle CEOs? And why don't clinical trials look like America?

Is biotech too founder-friendly? Is honesty overrated? And how do you tell a good beep from a bad one?

Should genome editors be worried? Has 2018 been a bummer? And are voters ready to love Big Pharma? We discuss this and more on a special live episode from the BioPharm America conference in Boston.

Is the FDA as lenient as everyone thinks? Can fish oil be a multibillion-dollar drug? And why aren't there better treatments for brain cancer?

Can genome-editing work in actual people? Are CEOs oversharing? And how do you sniff out a bad bet before it happens?

How much is a shot at curing cancer worth? Where are all the drugs for late-stage Alzheimer's disease? And what on Earth is an "oversubscribed Series A round"?

Can insider trading charges derail political campaigns? Should you trust a fund manager over a doctor? And how many rats would you trade for a cow?

What juicy perks do biotech startups offer to lure increasingly hard-to-find talent? How does Sanofi plan to make up for lost time in the lucrative field of oncology? And veteran biotech journalist Luke Timmerman talks about what it's like to climb Mt. Everest.

What qualifies as "robust" when it comes to data? Is digital health a bubble? And can Gilead Sciences survive without men named John?

Can drug prices swing an election? Is every quarter a “great quarter“? And why is everyone freaking out about CRISPR? Listen, and all will be explained.

Can phone calls bring down drug prices? Do mom-and-pop investors have a prayer against hedge funds? And how do you know whether an Alzheimer's drug actually works?

Adam and Damian recap the past six months in biotech. Investor and philanthropist, Sheff Station, stops by and gives tips on how to become a day trader, and analysts questioning their very existence.

How did the FDA become so friendly to the drug industry? The thorny issue of using 23andMe to unite families separated at the border, and Rebecca explains how drugs are priced in China.

Is Sarepta Therapeutics worth $10 billion? Will Theranos' Elizabeth Holmes go behind bars? And how does AI fit into biotech?

The problem with the topless dancers at PABNAB. Are investors overestimating the market for fatty liver drugs? And how many lives do biotech entrepreneurs get?

Why is Twitter so mean to Axovant? Adam teaches a crash course on biostatistics. And will sci-fi gene and cell therapies ever go mainstream.

Is the drug industry spending millions on a made-up disease? Have the latest cancer drugs been overhyped? And why does anyone go to BIO?

How worried should you be about Ebola? Can the government lower drug prices without hurting the drug industry? And is socceromics a thing? Listen this week to find out.

What do you call a unicorn without a horn? Is your colleague wearing a wire? And is Jentadueto a drug name or a complicated espresso drink?

On today's show, we dig into the no good, very bad day Novartis had when the world got wind of its ties to President Trump's personal attorney, a discussion of how the world's biggest cancer conference used to be the Wild West for investors, and an exploration of one health system's plan to bring genomics to the masses. Also STAT's Eric Boodman joins us to talk about how a pricey new gene therapy has created a fascinating situation in Amish country.

We talk to Bill Gates about the flu that could kill millions. Is China too enamored with biotech startups? And how do you find a cold case killer? Genetics.

What's a good use of $64 billion? Is Big Biotech boring now? And what's the best way to sell hair restoration products to men?

Is Bristol-Myers Squibb into self-sabotage? Is Congress coming for Gut Guy? And why does Goldman Sachs love money so much?

Why are biotech investors suddenly so exuberant? What does it mean when a CEO scrubs his LinkedIn profile? And can CRISPR turn your dog into a winged hellhound bent on destroying Chicago?

What's it like to be a biotech investor? Do you know where your genetic data are? And what does it mean when the FDA swipes left on your drug?

Why aren't pharma CEOs getting hauled into Congress? Which biotech companies got a failing grade this quarter? And why is there no Kelley Blue Book for the price tag of a medicine?

What’s it like to watch gene therapy happen? Is the next big cancer clinical trial going to work? And is “right to try” going to defang the FDA?

Did Elizabeth Holmes get off easy? Why does biotech bother with SXSW? And what does shoving a tube into a dead cow’s throat have to do with biotech?

How long is Martin Shkreli going to be in prison? Is the biotech bubble about to burst? And what's it like to attend a blood-swapping gala? Listen to our first episode of, "The Readout LOUD."

An introduction to a new weekly biotech podcast from STAT.